GlassScriptPhysician profile
Sandra Rene Stine
NPI 1790768356
$4,353.33
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $844 · 2020: $851 · 2021: $666 · 2022: $946 · 2023: $982 · 2024: $64.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $505.64 | 2019-2023 | Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $503.63 | 2019-2023 | Farxiga, Breztri |
| Amgen INC. | $410.78 | 2019-2023 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.93 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $386.86 | 2019-2023 | Shingrix, Arexvy |
| Novo Nordisk INC | $335.04 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $278.30 | 2022-2024 | Freestyle Libre 3, Proclaim, Jot Dx |
| Allergan, INC. | $200.53 | 2019-2020 | |
| Pfizer INC. | $174.25 | 2019-2023 | |
| Lilly USA, LLC | $164.93 | 2020-2023 | Mounjaro |
| Amarin Pharma, INC. | $135.52 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $114.30 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.69 | 2019-2021 | |
| Astellas Pharma US INC | $81.42 | 2021-2023 | Veozah |
| Esperion Therapeutics, INC. | $77.36 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $52.02 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $41.35 | 2019-2021 | |
| Dynavax Technologies Corporation | $39.82 | 2022-2023 | Heplisav-B |
| Exact Sciences Corporation | $36.57 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $36.17 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $35.37 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.14 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $29.93 | 2023 | |
| Eisai INC. | $27.40 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $27.07 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $24.23 | 2019 | |
| Ascend Therapeutics US, LLC | $20.00 | 2021 | |
| Medtronic, INC. | $18.34 | 2021 | |
| Hologic Sales and Service, LLC | $18.30 | 2023 | Thinprep 2000 Processor, Aptima |
| Otsuka America Pharmaceutical, INC. | $17.88 | 2022 | |
| Sanofi Pasteur INC. | $15.09 | 2020 | |
| Amneal Pharmaceuticals LLC | $13.26 | 2021 | |
| Vistapharm, INC. | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Stine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.